Evidence map›Paper›PMID 32424463›Full record

ReviewDer Radiologe2020

Hybrid imaging of the abdomen and pelvis.

Krista Elise Suarez-Weiss, Alexander Herold, Debra Gervais, Edwin Palmer, Bárbara Amorim, Joseph D King, Li Weier, Tajmir Shahein, Hanna Bernstine, Liran Domachevsk and 5 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Radiologe, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Krista Elise Suarez-WeissDivision of Abdominal Radiology, Massachusetts General Hospital, Boston, MA, USA.
Alexander HeroldUniversity of Vienna, Vienna, Austria.
Debra GervaisDivision of Abdominal Radiology, Massachusetts General Hospital, Boston, MA, USA.
Edwin PalmerDivision of Abdominal Radiology, Massachusetts General Hospital, Boston, MA, USA.
Bárbara AmorimCampinas State University, Campinas, Brazil.
Joseph D KingDivision of Abdominal Radiology, Massachusetts General Hospital, Boston, MA, USA.
Li WeierDivision of Abdominal Radiology, Massachusetts General Hospital, Boston, MA, USA.
Tajmir ShaheinDivision of Abdominal Radiology, Massachusetts General Hospital, Boston, MA, USA.
Hanna BernstineTel Aviv University, Tel Aviv, Israel.
Liran DomachevskTel Aviv University, Tel Aviv, Israel.
Lina Garcia CañamaqueHM Hospitales, Madrid, Spain.
Ken Herrmann
Lale Umutlu
David GrosharTel Aviv University, Tel Aviv, Israel.
Onofrio A CatalanoDivision of Abdominal Radiology, Massachusetts General Hospital, Boston, MA, USA. ocatalano@mgh.harvard.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate imaging is crucial for lesion detection in abdominal organs, for the noninvasive characterization of focal and diffuse abnormalities, and for surgical planning. To accomplish these tasks, several imaging modalities such as multidetector computer tomography (MDCT), magnetic resonance imaging (MRI) and positron emission tomography/computed tomography (PET/CT) are used for abdominal imaging, providing important morphological, functional or metabolic information. More recently, PET/MRI has been gaining attention due to the possibility of combining high-resolution imaging with metabolic imaging. PET/MRI is a novel hybrid imaging technology that in the near future might play a pivotal role in the clinical management of oncologic and inflammatory abdominopelvic diseases. Despite the still limited number of published clinical studies, PET/MRI has been proven to be at least equivalent to PET/CT and to standalone MRI in a variety of oncologic disease. Moreover, in selected and focused clinical studies, it has been proven to outperform current standard of care imaging, for example, in evaluating cholangiocarcinomas, liver metastases, untreated and treated rectal cancer. This has also had an impact on therapeuticmanagement in some studies. Therefore in some institutions, including those of the authors, PET/MRI is becoming the new standard imaging modality in staging treatment-naïve intrahepatic massforming cholangiocarcinomas and prior to complicated hepatic surgery.

Indexed as

AbdomenMultimodal ImagingPelvisHumansCholangiocarcinomaLiverPositron emission tomography/magnetic resonance imagingRectumStaging

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.